News and Press

NEW ORAL ANTICOAGULANTS
Rivaroxaban : Advisory Board recommends approval of rivaroxaban in AF by the FDA

The new oral anticoagulant rivaroxaban (Xarelto®), a Xa inhibitor of Bayer HealthCare and Johnson & Johnson, was recently recommended for approval for prevention of stroke by the Food and Drug Administration (FDA) following the ROCKET AF Study presented at the American Heart Association 2010 and published in the New England Journal of Medicine(1).
Read more

NEW ORAL ANTICOAGULANTS
ESC Congress in Paris: ARISTOTLE Trial showed superiority over warfarin in atrial fibrillation

On August 28, 2011, Granger C, Wallentin L et al. (1) reported the results of the ARISTOTLE trial (1,2) which evaluated the efficacy and safety of apixaban (Bristol-Myers Squibb and Pfizer) compared to warfarin in stroke prevention and systemic embolism in patients with nonvalvular atrial fibrillation and an additional risk factor for stroke. This randomized, multicenter trial included 18201 patients randomized to apixaban (5mg b.i.d.) or adjusted dose warfarin. The primary endpoint was stroke (ischemic or hemorrhagic) or systemic embolism. The secondary endpoint included efficacy and major bleeding and death of any cause.
Read more

News and Press

NEW ORAL ANTICOAGULANTS Rivaroxaban : Advisory Board recommends approval of rivaroxaban in AF by the FDA

NEW ORAL ANTICOAGULANTS ESC Congress in Paris: ARISTOTLE Trial showed superiority over warfarin in atrial fibrillation

NEW ORAL ANTICOAGULANTS
Rivaroxaban : Advisory Board recommends approval of rivaroxaban in AF by the FDA

NEW ORAL ANTICOAGULANTS
ESC Congress in Paris: ARISTOTLE Trial showed superiority over warfarin in atrial fibrillation